Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15728485rdf:typepubmed:Citationlld:pubmed
pubmed-article:15728485lifeskim:mentionsumls-concept:C0206430lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C0024518lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C0013682lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:15728485lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:15728485pubmed:issue5lld:pubmed
pubmed-article:15728485pubmed:dateCreated2005-2-24lld:pubmed
pubmed-article:15728485pubmed:abstractTextEvidence suggests that most epitopes presented by MHC class I molecules are derived from those newly synthesized proteins that are defective due to errors during manufacture. We examined epitope production from model cytosolic and exocytic proteins modified in various ways. Substrates containing a degradation targeting sequence demonstrated very rapid turnover and enhanced epitope production, as was the case for substrate retargeted from endoplasmic reticulum to cytosol. For less radical alterations, including point mutation and deletion and elimination of glycosylation sites, despite detectable changes in folding, half-life was only moderately decreased and there were no significant increases in epitope production. Puromycin, which causes premature termination of protein synthesis, also had no impact upon epitope production. It appears that most defective proteins are not rapidly dispensed with and the targeting of most nascent proteins for Ag processing is not tied to quality control.lld:pubmed
pubmed-article:15728485pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:languageenglld:pubmed
pubmed-article:15728485pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15728485pubmed:statusMEDLINElld:pubmed
pubmed-article:15728485pubmed:monthMarlld:pubmed
pubmed-article:15728485pubmed:issn0022-1767lld:pubmed
pubmed-article:15728485pubmed:authorpubmed-author:GolovinaTatia...lld:pubmed
pubmed-article:15728485pubmed:authorpubmed-author:EisenlohrLaur...lld:pubmed
pubmed-article:15728485pubmed:authorpubmed-author:MorrisonSusan...lld:pubmed
pubmed-article:15728485pubmed:issnTypePrintlld:pubmed
pubmed-article:15728485pubmed:day1lld:pubmed
pubmed-article:15728485pubmed:volume174lld:pubmed
pubmed-article:15728485pubmed:ownerNLMlld:pubmed
pubmed-article:15728485pubmed:authorsCompleteYlld:pubmed
pubmed-article:15728485pubmed:pagination2763-9lld:pubmed
pubmed-article:15728485pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:meshHeadingpubmed-meshheading:15728485...lld:pubmed
pubmed-article:15728485pubmed:year2005lld:pubmed
pubmed-article:15728485pubmed:articleTitleThe impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing.lld:pubmed
pubmed-article:15728485pubmed:affiliationDepartment of Microbiology and Immunology, Jefferson Medical College and Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107, USA.lld:pubmed
pubmed-article:15728485pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15728485pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15728485pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15728485pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15728485lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15728485lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15728485lld:pubmed